Jommi, Claudio, and Marianna Cavazza. 2019. “Management of Patients Eligible for Proprotein Convertase subtilisin/kexin Type 9 (PCSK9) Inhibitors: Economic Impact and Reform Proposals”. Global and Regional Health Technology Assessment 6 (1). https://doi.org/10.33393/grhta.2019.460.